English
简体中文
Total: £ 56.28
Published Date: 2026-04-08 | Pages: 119 | Tables: 120 | Service & Software
The global Innovative Drug CDMO market was valued at US$ 2930 million in 2025 and is anticipated to reach US$ 5139 million by 2032, at a CAGR of 8.5% from 2026 to 2032.
Innovative Drug CDMO is partner that provide customized, integrated outsourcing services for the research and development and commercial manufacturing of innovative drugs (including chemical drugs, biologics, and cell and gene therapy products). Their business spans the entire lifecycle of a drug, from preclinical development to post-market supply, specifically covering core aspects such as process development and optimization, process scale-up of active pharmaceutical ingredients (APIs) and formulations, clinical sample production, commercial manufacturing, packaging, and registration support. CDMOs not only provide manufacturing facilities and capacity that meet global Good Manufacturing Practice (GMP) requirements, but also leverage their expertise and experience to help pharmaceutical companies reduce R&D costs, shorten development cycles, and control production risks, allowing them to focus more on core drug discovery and clinical research. This model has become a key support for the refined division of labor and improved efficiency in the global biopharmaceutical industry.
The costs of an innovative drug CDMO primarily consist of highly skilled personnel, depreciation of cutting-edge R&D equipment, GMP-compliant production consumables and quality control, and project management fees. Their gross profit margin typically ranges from 30% to 50%, depending on the added value of the technology, the project stage, and capacity utilization. Early-stage R&D projects often have higher gross profit margins due to their high degree of customization and small-scale production; while large-scale commercial production relies on stable processes and high capacity utilization to maintain substantial profits. Leading companies with cutting-edge technology platforms typically enjoy higher gross profit margins.
The global innovative drug CDMO market is characterized by a "three-pronged approach and multiple emerging players." North America, as the world's largest market and innovation hub, boasts the most mature biotechnology ecosystem and leading technology platforms, dominating industry standards and development directions. Europe, with its strong pharmaceutical industrial foundation, maintains a powerful presence in chemical drugs and some biologics, with a particular focus on quality systems and complex formulation technologies. The Asia-Pacific region, especially China, is the fastest-growing engine, driven by the rise of domestic innovative drugs, the return of talent, and cost advantages. It is rapidly upgrading from "capacity export" to "technology-driven" development, with South Korea and India also actively participating in their respective areas of strength. The global supply chain is accelerating its integration, with technological capabilities, production capacity, and geopolitical factors jointly influencing customers' regional choices, resulting in a trend towards diversified and regionalized supply chain layouts.
This report delivers a comprehensive overview of the global Innovative Drug CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Innovative Drug CDMO. The Innovative Drug CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Innovative Drug CDMO market comprehensively. Regional market sizes by Type, by Application, by Service Stage, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Innovative Drug CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Skyepharma
Asymchem
Recipharm
Bend Bioscience
Pierre Fabre
Axplora
Quotient Sciences
Lonza
Ardena
Hovione
Resilience
AGC Biologics
Patheon Pharma Services
Samsung Biologics
Catalent
Segment by Type
Small Molecule CDMO
Macromolecule CDMO
Cell Gene Therapy (CGT) CDMO
Segment by Service Stage
Early-stage R&D CDMO
Commercial Production CDMO
Segment by Business Model
Capacity-driven
Technology-driven
Segment by Application
Oncology and Cancer Drugs
Autoimmune Disease Drugs
Rare Disease Drugs
Gene Therapy Drugs
Metabolic Disease Drugs
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Service Stage, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Innovative Drug CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Innovative Drug CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Small Molecule CDMO
1.2.3 Macromolecule CDMO
1.2.4 Cell Gene Therapy (CGT) CDMO
1.3 Market by Service Stage
1.3.1 Global Innovative Drug CDMO Market Size Growth Rate by Service Stage: 2021 vs 2025 vs 2032
1.3.2 Early-stage R&D CDMO
1.3.3 Commercial Production CDMO
1.4 Market by Business Model
1.4.1 Global Innovative Drug CDMO Market Size Growth Rate by Business Model: 2021 vs 2025 vs 2032
1.4.2 Capacity-driven
1.4.3 Technology-driven
1.5 Market by Application
1.5.1 Global Innovative Drug CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Oncology and Cancer Drugs
1.5.3 Autoimmune Disease Drugs
1.5.4 Rare Disease Drugs
1.5.5 Gene Therapy Drugs
1.5.6 Metabolic Disease Drugs
1.5.7 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Innovative Drug CDMO Market Perspective (2021–2032)
2.2 Global Innovative Drug CDMO Growth Trends by Region
2.2.1 Global Innovative Drug CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Innovative Drug CDMO Historic Market Size by Region (2021–2026)
2.2.3 Innovative Drug CDMO Forecasted Market Size by Region (2027–2032)
2.3 Innovative Drug CDMO Market Dynamics
2.3.1 Innovative Drug CDMO Industry Trends
2.3.2 Innovative Drug CDMO Market Drivers
2.3.3 Innovative Drug CDMO Market Challenges
2.3.4 Innovative Drug CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Innovative Drug CDMO Players by Revenue
3.1.1 Global Top Innovative Drug CDMO Players by Revenue (2021–2026)
3.1.2 Global Innovative Drug CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Innovative Drug CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Innovative Drug CDMO Revenue
3.4 Global Innovative Drug CDMO Market Concentration Ratio
3.4.1 Global Innovative Drug CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Innovative Drug CDMO Revenue in 2025
3.5 Global Key Players of Innovative Drug CDMO Head Offices and Areas Served
3.6 Global Key Players of Innovative Drug CDMO, Products and Applications
3.7 Global Key Players of Innovative Drug CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Innovative Drug CDMO Breakdown Data by Type
4.1 Global Innovative Drug CDMO Historic Market Size by Type (2021–2026)
4.2 Global Innovative Drug CDMO Forecasted Market Size by Type (2027–2032)
5 Innovative Drug CDMO Breakdown Data by Application
5.1 Global Innovative Drug CDMO Historic Market Size by Application (2021–2026)
5.2 Global Innovative Drug CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Innovative Drug CDMO Market Size (2021–2032)
6.2 North America Innovative Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Innovative Drug CDMO Market Size by Country (2021–2026)
6.4 North America Innovative Drug CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Innovative Drug CDMO Market Size (2021–2032)
7.2 Europe Innovative Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Innovative Drug CDMO Market Size by Country (2021–2026)
7.4 Europe Innovative Drug CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Innovative Drug CDMO Market Size (2021–2032)
8.2 Asia-Pacific Innovative Drug CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Innovative Drug CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Innovative Drug CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Innovative Drug CDMO Market Size (2021–2032)
9.2 Latin America Innovative Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Innovative Drug CDMO Market Size by Country (2021–2026)
9.4 Latin America Innovative Drug CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Innovative Drug CDMO Market Size (2021–2032)
10.2 Middle East & Africa Innovative Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Innovative Drug CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Innovative Drug CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Skyepharma
11.1.1 Skyepharma Company Details
11.1.2 Skyepharma Business Overview
11.1.3 Skyepharma Innovative Drug CDMO Introduction
11.1.4 Skyepharma Revenue in Innovative Drug CDMO Business (2021–2026)
11.1.5 Skyepharma Recent Development
11.2 Asymchem
11.2.1 Asymchem Company Details
11.2.2 Asymchem Business Overview
11.2.3 Asymchem Innovative Drug CDMO Introduction
11.2.4 Asymchem Revenue in Innovative Drug CDMO Business (2021–2026)
11.2.5 Asymchem Recent Development
11.3 Recipharm
11.3.1 Recipharm Company Details
11.3.2 Recipharm Business Overview
11.3.3 Recipharm Innovative Drug CDMO Introduction
11.3.4 Recipharm Revenue in Innovative Drug CDMO Business (2021–2026)
11.3.5 Recipharm Recent Development
11.4 Bend Bioscience
11.4.1 Bend Bioscience Company Details
11.4.2 Bend Bioscience Business Overview
11.4.3 Bend Bioscience Innovative Drug CDMO Introduction
11.4.4 Bend Bioscience Revenue in Innovative Drug CDMO Business (2021–2026)
11.4.5 Bend Bioscience Recent Development
11.5 Pierre Fabre
11.5.1 Pierre Fabre Company Details
11.5.2 Pierre Fabre Business Overview
11.5.3 Pierre Fabre Innovative Drug CDMO Introduction
11.5.4 Pierre Fabre Revenue in Innovative Drug CDMO Business (2021–2026)
11.5.5 Pierre Fabre Recent Development
11.6 Axplora
11.6.1 Axplora Company Details
11.6.2 Axplora Business Overview
11.6.3 Axplora Innovative Drug CDMO Introduction
11.6.4 Axplora Revenue in Innovative Drug CDMO Business (2021–2026)
11.6.5 Axplora Recent Development
11.7 Quotient Sciences
11.7.1 Quotient Sciences Company Details
11.7.2 Quotient Sciences Business Overview
11.7.3 Quotient Sciences Innovative Drug CDMO Introduction
11.7.4 Quotient Sciences Revenue in Innovative Drug CDMO Business (2021–2026)
11.7.5 Quotient Sciences Recent Development
11.8 Lonza
11.8.1 Lonza Company Details
11.8.2 Lonza Business Overview
11.8.3 Lonza Innovative Drug CDMO Introduction
11.8.4 Lonza Revenue in Innovative Drug CDMO Business (2021–2026)
11.8.5 Lonza Recent Development
11.9 Ardena
11.9.1 Ardena Company Details
11.9.2 Ardena Business Overview
11.9.3 Ardena Innovative Drug CDMO Introduction
11.9.4 Ardena Revenue in Innovative Drug CDMO Business (2021–2026)
11.9.5 Ardena Recent Development
11.10 Hovione
11.10.1 Hovione Company Details
11.10.2 Hovione Business Overview
11.10.3 Hovione Innovative Drug CDMO Introduction
11.10.4 Hovione Revenue in Innovative Drug CDMO Business (2021–2026)
11.10.5 Hovione Recent Development
11.11 Resilience
11.11.1 Resilience Company Details
11.11.2 Resilience Business Overview
11.11.3 Resilience Innovative Drug CDMO Introduction
11.11.4 Resilience Revenue in Innovative Drug CDMO Business (2021–2026)
11.11.5 Resilience Recent Development
11.12 AGC Biologics
11.12.1 AGC Biologics Company Details
11.12.2 AGC Biologics Business Overview
11.12.3 AGC Biologics Innovative Drug CDMO Introduction
11.12.4 AGC Biologics Revenue in Innovative Drug CDMO Business (2021–2026)
11.12.5 AGC Biologics Recent Development
11.13 Patheon Pharma Services
11.13.1 Patheon Pharma Services Company Details
11.13.2 Patheon Pharma Services Business Overview
11.13.3 Patheon Pharma Services Innovative Drug CDMO Introduction
11.13.4 Patheon Pharma Services Revenue in Innovative Drug CDMO Business (2021–2026)
11.13.5 Patheon Pharma Services Recent Development
11.14 Samsung Biologics
11.14.1 Samsung Biologics Company Details
11.14.2 Samsung Biologics Business Overview
11.14.3 Samsung Biologics Innovative Drug CDMO Introduction
11.14.4 Samsung Biologics Revenue in Innovative Drug CDMO Business (2021–2026)
11.14.5 Samsung Biologics Recent Development
11.15 Catalent
11.15.1 Catalent Company Details
11.15.2 Catalent Business Overview
11.15.3 Catalent Innovative Drug CDMO Introduction
11.15.4 Catalent Revenue in Innovative Drug CDMO Business (2021–2026)
11.15.5 Catalent Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Innovative Drug CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Small Molecule CDMO
Table 3. Key Players of Macromolecule CDMO
Table 4. Key Players of Cell Gene Therapy (CGT) CDMO
Table 5. Global Innovative Drug CDMO Market Size Growth Rate by Service Stage (US$ Million): 2021 vs 2025 vs 2032
Table 6. Key Players of Early-stage R&D CDMO
Table 7. Key Players of Commercial Production CDMO
Table 8. Global Innovative Drug CDMO Market Size Growth Rate by Business Model (US$ Million): 2021 vs 2025 vs 2032
Table 9. Key Players of Capacity-driven
Table 10. Key Players of Technology-driven
Table 11. Global Innovative Drug CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 12. Global Innovative Drug CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 13. Global Innovative Drug CDMO Market Size by Region (US$ Million), 2021–2026
Table 14. Global Innovative Drug CDMO Market Share by Region (2021–2026)
Table 15. Global Innovative Drug CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 16. Global Innovative Drug CDMO Market Share by Region (2027–2032)
Table 17. Innovative Drug CDMO Market Trends
Table 18. Innovative Drug CDMO Market Drivers
Table 19. Innovative Drug CDMO Market Challenges
Table 20. Innovative Drug CDMO Market Restraints
Table 21. Global Innovative Drug CDMO Revenue by Players (US$ Million), 2021–2026
Table 22. Global Innovative Drug CDMO Market Share by Players (2021–2026)
Table 23. Global Top Innovative Drug CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Innovative Drug CDMO Revenue, 2025
Table 24. Ranking of Global Top Innovative Drug CDMO Companies by Revenue (US$ Million) in 2025
Table 25. Global 5 Largest Players Market Share by Innovative Drug CDMO Revenue (CR5 and HHI), 2021–2026
Table 26. Global Key Players of Innovative Drug CDMO, Headquarters and Area Served
Table 27. Global Key Players of Innovative Drug CDMO, Products and Applications
Table 28. Global Key Players of Innovative Drug CDMO, Date of General Availability (GA)
Table 29. Mergers and Acquisitions, Expansion Plans
Table 30. Global Innovative Drug CDMO Market Size by Type (US$ Million), 2021–2026
Table 31. Global Innovative Drug CDMO Revenue Market Share by Type (2021–2026)
Table 32. Global Innovative Drug CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 33. Global Innovative Drug CDMO Revenue Market Share by Type (2027–2032)
Table 34. Global Innovative Drug CDMO Market Size by Application (US$ Million), 2021–2026
Table 35. Global Innovative Drug CDMO Revenue Market Share by Application (2021–2026)
Table 36. Global Innovative Drug CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 37. Global Innovative Drug CDMO Revenue Market Share by Application (2027–2032)
Table 38. North America Innovative Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 39. North America Innovative Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 40. North America Innovative Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 41. Europe Innovative Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Europe Innovative Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 43. Europe Innovative Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 44. Asia-Pacific Innovative Drug CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 45. Asia-Pacific Innovative Drug CDMO Market Size by Region (US$ Million), 2021–2026
Table 46. Asia-Pacific Innovative Drug CDMO Market Size by Region (US$ Million), 2027–2032
Table 47. Latin America Innovative Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 48. Latin America Innovative Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 49. Latin America Innovative Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 50. Middle East & Africa Innovative Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 51. Middle East & Africa Innovative Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 52. Middle East & Africa Innovative Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 53. Skyepharma Company Details
Table 54. Skyepharma Business Overview
Table 55. Skyepharma Innovative Drug CDMO Product
Table 56. Skyepharma Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 57. Skyepharma Recent Development
Table 58. Asymchem Company Details
Table 59. Asymchem Business Overview
Table 60. Asymchem Innovative Drug CDMO Product
Table 61. Asymchem Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 62. Asymchem Recent Development
Table 63. Recipharm Company Details
Table 64. Recipharm Business Overview
Table 65. Recipharm Innovative Drug CDMO Product
Table 66. Recipharm Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 67. Recipharm Recent Development
Table 68. Bend Bioscience Company Details
Table 69. Bend Bioscience Business Overview
Table 70. Bend Bioscience Innovative Drug CDMO Product
Table 71. Bend Bioscience Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 72. Bend Bioscience Recent Development
Table 73. Pierre Fabre Company Details
Table 74. Pierre Fabre Business Overview
Table 75. Pierre Fabre Innovative Drug CDMO Product
Table 76. Pierre Fabre Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 77. Pierre Fabre Recent Development
Table 78. Axplora Company Details
Table 79. Axplora Business Overview
Table 80. Axplora Innovative Drug CDMO Product
Table 81. Axplora Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 82. Axplora Recent Development
Table 83. Quotient Sciences Company Details
Table 84. Quotient Sciences Business Overview
Table 85. Quotient Sciences Innovative Drug CDMO Product
Table 86. Quotient Sciences Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 87. Quotient Sciences Recent Development
Table 88. Lonza Company Details
Table 89. Lonza Business Overview
Table 90. Lonza Innovative Drug CDMO Product
Table 91. Lonza Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 92. Lonza Recent Development
Table 93. Ardena Company Details
Table 94. Ardena Business Overview
Table 95. Ardena Innovative Drug CDMO Product
Table 96. Ardena Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 97. Ardena Recent Development
Table 98. Hovione Company Details
Table 99. Hovione Business Overview
Table 100. Hovione Innovative Drug CDMO Product
Table 101. Hovione Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 102. Hovione Recent Development
Table 103. Resilience Company Details
Table 104. Resilience Business Overview
Table 105. Resilience Innovative Drug CDMO Product
Table 106. Resilience Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 107. Resilience Recent Development
Table 108. AGC Biologics Company Details
Table 109. AGC Biologics Business Overview
Table 110. AGC Biologics Innovative Drug CDMO Product
Table 111. AGC Biologics Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 112. AGC Biologics Recent Development
Table 113. Patheon Pharma Services Company Details
Table 114. Patheon Pharma Services Business Overview
Table 115. Patheon Pharma Services Innovative Drug CDMO Product
Table 116. Patheon Pharma Services Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 117. Patheon Pharma Services Recent Development
Table 118. Samsung Biologics Company Details
Table 119. Samsung Biologics Business Overview
Table 120. Samsung Biologics Innovative Drug CDMO Product
Table 121. Samsung Biologics Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 122. Samsung Biologics Recent Development
Table 123. Catalent Company Details
Table 124. Catalent Business Overview
Table 125. Catalent Innovative Drug CDMO Product
Table 126. Catalent Revenue in Innovative Drug CDMO Business (US$ Million), 2021–2026
Table 127. Catalent Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Innovative Drug CDMO Picture
Figure 2. Global Innovative Drug CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Innovative Drug CDMO Market Share by Type: 2025 vs 2032
Figure 4. Small Molecule CDMO Features
Figure 5. Macromolecule CDMO Features
Figure 6. Cell Gene Therapy (CGT) CDMO Features
Figure 7. Global Innovative Drug CDMO Market Size Comparison by Service Stage (US$ Million), 2021–2032
Figure 8. Early-stage R&D CDMO Features
Figure 9. Commercial Production CDMO Features
Figure 10. Global Innovative Drug CDMO Market Size Comparison by Business Model (US$ Million), 2021–2032
Figure 11. Capacity-driven Features
Figure 12. Technology-driven Features
Figure 13. Global Innovative Drug CDMO Market Size by Application (US$ Million), 2021–2032
Figure 14. Global Innovative Drug CDMO Market Share by Application: 2025 vs 2032
Figure 15. Oncology and Cancer Drugs Case Studies
Figure 16. Autoimmune Disease Drugs Case Studies
Figure 17. Rare Disease Drugs Case Studies
Figure 18. Gene Therapy Drugs Case Studies
Figure 19. Metabolic Disease Drugs Case Studies
Figure 20. Others Case Studies
Figure 21. Innovative Drug CDMO Report Years Considered
Figure 22. Global Innovative Drug CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 23. Global Innovative Drug CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Innovative Drug CDMO Market Share by Region: 2025 vs 2032
Figure 25. Global Innovative Drug CDMO Market Share by Players in 2025
Figure 26. Global Innovative Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Innovative Drug CDMO Revenue in 2025
Figure 28. North America Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. North America Innovative Drug CDMO Market Share by Country (2021–2032)
Figure 30. United States Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Canada Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Europe Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Europe Innovative Drug CDMO Market Share by Country (2021–2032)
Figure 34. Germany Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. France Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. U.K. Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Italy Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Russia Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Ireland Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Asia-Pacific Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Asia-Pacific Innovative Drug CDMO Market Share by Region (2021–2032)
Figure 42. China Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Japan Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. South Korea Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Southeast Asia Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. India Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Australia & New Zealand Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Latin America Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Latin America Innovative Drug CDMO Market Share by Country (2021–2032)
Figure 50. Mexico Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Brazil Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Middle East & Africa Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Middle East & Africa Innovative Drug CDMO Market Share by Country (2021–2032)
Figure 54. Israel Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. Saudi Arabia Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 56. UAE Innovative Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. Skyepharma Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 58. Asymchem Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 59. Recipharm Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 60. Bend Bioscience Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 61. Pierre Fabre Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 62. Axplora Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 63. Quotient Sciences Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 64. Lonza Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 65. Ardena Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 66. Hovione Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 67. Resilience Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 68. AGC Biologics Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 69. Patheon Pharma Services Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 70. Samsung Biologics Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 71. Catalent Revenue Growth Rate in Innovative Drug CDMO Business (2021–2026)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
